We recently generated two phenotypically similar Hoxa9+Meis1 overexpressing acute myeloid leukemias that differ by their in vivo biological behavior. The first leukemia, named FLA2, shows a high frequency of leukemia stem cells (LSC: 1 in 1.4 cell) whereas the second, FLB1, is more typical with a frequency of LSC in the range of 1 per several hundred cells. To gain insights into possible mechanisms that determine LSC selfrenewal, we profiled and compared the abundance of nuclear and cytoplasmic proteins and phosphoproteins from these leukemias using quantitative proteomics. These analyses revealed differences in proteins associated with stem cell fate, including a hyperactive p38 MAP kinase in FLB1 and a differentially localized Polycomb Group protein Ezh2 which is mostly nuclear in FLA2 and predominantly cytoplasmic in FLB1. Together, these newly documented proteomes and phosphoproteomes represent a unique resource with over 440 differentially expressed proteins and 11,543 unique phosphopeptides, of which 80% are novel and 7% preferentially phosphorylated in the stem cell-enriched leukemia.
INTRODUCTION
Pioneer studies by Dick and collaborators 1 exposed that a significant proportion of human leukemias are hierarchically organized. Although the majority of cells in these leukemias show limited proliferative capacity, their production is continuously ensured by a much less frequent population termed leukemia stem cells (LSCs) which display unlimited selfrenewal potential. In contrast to normal (i.e. non-leukemic) hematopoietic stem cells (HSC), which can be purified by flow cytometry to near functional homogeneity, the prospective isolation of LSC has proven more difficult to achieve. Inter-specimen variation in cell surface marker expression attributed to LSC is, at least in part, responsible for this difficulty. For this reason, functional in vivo studies remain the gold standard assay for quantitative assessment of LSC numbers in any given specimen. 2, 3 Original studies which took advantage of NOD-scid recipient mice for LSC evaluation in human acute myeloid leukemia (AML) reported considerable variations in LSC frequencies, ranging from 1 in 10 4 to 1 per 10 7 cells. 2 Additional depletion of the recipient's NK cells using NOD/ShiLtSz-scid/IL2Rγ null (NSG) or NOD/ShiJic-scid/IL-2Rγ null (NOG) mice considerably improved LSC detection. 4 Such studies highlighted the important contribution of host factors in LSC frequency assessment. These factors could be minimized through the exploitation of a syngenic model system (e.g., mouse leukemias transplanted into syngenic or congenic recipients). For example, LSC frequencies of ~1% were observed in E2a-Pbx1+Hoxa9 or MLL-AF9-induced mouse AML, whereas frequencies of 0.01% were found in MOZ-TIF AML, respectively [5] [6] [7] .
Together, these studies confirmed the relatively low LSC frequency in AML.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Thus, two outstanding issues, one related to low LSC abundance and the other to reliable cell surface markers for LSC isolation, still limit our ability to obtain a sufficiently high number of pure LSC that can be used for comprehensive proteomic or phosphoproteomic studies. To overcome these hurdles, our group recently generated several closely related Hoxa9 + Meis1 overexpressing acute myeloid leukemias derived from phenotypically primitive mouse fetal liver cells. These leukemias express similar levels of the Hoxa9 and Meis1 oncogenes, have a normal karyotype and do not harbor any coarse chromosomal abnormalities. 8 They also display the same cell surface marker phenotype (c-Kit + Sca1 -CD150 -CD48 + CD34 + CD71 + Mac1 + GR1 + ), cell cycle profile and dissemination characteristics. Despite this remarkable similarity, two of these leukemias exhibit very different LSC frequencies, ranging from 1 in 1.4 (~71%) for FLA2 to 1 in 347 (~0.3%) for FLB1. 8 Importantly, the difference in LSC frequencies between FLA2 and FLB1 leukemias has remained stable over successive transplantations. These leukemias are clinically relevant since the Hoxa9 and Meis1 oncogenes are overexpressed in a large proportion of human leukemias, are transcriptional targets of MLL fusion proteins and have been shown to be key regulators of LSC self-renewal. [9] [10] [11] Unlike other leukemia mouse models, high numbers of an almost pure population of LSCs can be readily obtained from FLA2 without the need for purification using cell surface markers.
Therefore, FLA2 and FLB1 leukemias represent a unique model system to dissect the molecular machinery underlying the self-renewal of LSCs. To this end, transcriptome analysis using next generation RNA sequencing revealed hundreds of differentially expressed genes and numerous structural differences (alternative splicing and promoter usage). 8 For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Using the same FLA2/FLB1 leukemia model, we now report the first ever described comparative proteome and phosphoproteome of two highly similar leukemias, one of which is made of almost pure LSCs. Our results show that several novel candidate proteins are differentially expressed or phosphorylated between FLA2 and FLB1, including the Polycomb Group (PcG) proteins Ezh2 and Suz12. These results represent a unique resource for the dissection of signaling pathways that are active in LSCs.
EXPERIMENTAL PROCEDURES

Generation of FLA2 and FLB1 primary mouse leukemias
FLA2 and FLB1 primary mouse leukemias were generated as described previously. 8 See supplementary methods for details. Experimental procedures were approved by the Université de Montréal animal ethics committee.
Expression analyses using SDS-PAGE and Mass Spectrometry
Biological replicates (n=3, 20 μ g each) of FLA2 and FLB1 nuclear and cytosolic extracts were reduced with tris(2-carboxyethyl)phosphine (TCEP) (Pierce), alkylated with iodoacetamide (Sigma-Aldrich) and separated on a 4-12% pre-cast NuPAGE gel (Invitrogen). The gel was stained with colloidal coomassie and 12 bands of equal size were excised using a custom cutting device. Proteins were reduced, alkylated with iodoacetamide, digested with trypsin and peptides extracted as described before. 12 Samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) on an LTQ-Orbitrap mass spectrometer (Thermo Fischer Scientific) using a 65 min linear gradient. See supplementary methods for details. 
Phosphopeptide enrichment and Mass Spectrometry
Nuclear and cytosolic protein extracts (pooled from 5 mice, 1.2 mg each, n=3 independent experiments) were reduced, alkylated with iodoacetamide and digested with trypsin (Promega). Phosphopeptides were enriched on custom TiO 2 -microcolumns (GL Science) as described previously. 12, 13 Phosphopeptides were analyzed using online 2D-LC-MS/MS on an LTQ-Orbitrap mass spectrometer. Phosphopeptide samples were loaded on a self-packed 45mm x 300 μ m Polysulfoethyl column (Nest Group, Southborough, MA) and eluted with increasing salt fractions (0, 0.05, 0.075, 0.1, 0.5, and 2.0 M ammonium acetate in 2% ACN, 0.2% formic acid, pH 3.0). Eluted salt fractions were then analyzed directly by LC-MS/MS as described above. 12 See supplementary methods for details.
Protein identification and bioinformatic analyses
MS/MS spectra were processed and analysed as described before. 12 Protein and peptide identifications are available online via ProteoConnections 14 at s. Gene-ontology and STRING analysis was also performed as before. 12 See supplementary methods for details.
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RESULTS
Subcellular quantitative analysis of proteome and phosphoproteome of FLA2 and FLB1 leukemias
Nuclear and cytosolic protein extracts were generated from freshly harvested FLA2 and FLB1 leukemias acquired from 15 different mice. Three biological replicates were generated by combining the protein extracts from five mice. Purity of the nuclear and cytosolic fractions was assessed for each specimen ( Figure S1A ). A two pronged approach based on label-free quantitative proteomics was used to profile both changes in protein abundance and phosphorylation stoichiometry in the corresponding nuclear and cytosolic extracts ( Figure S1B ). Comparative MS analysis of these extracts on an LTQ-Orbitrap mass spectrometer led to the identification of 24,320 unique peptides from 2,348 proteins with an average sequence coverage of 24% and a false-discovery rate (FDR) <1% using a forward and reverse IPI mouse database. We correlated the changes in abundance of 12,749 unique peptides (2,655 proteins) using label-free quantitative proteomics where 95% of peptide clusters showed a relative standard deviation (RSD) less than 53% (1.53-fold) across biological replicates ( Figure S1C ). Although expression levels between FLB1 and FLA2 remained unaffected for most identified proteins, a subset of 442 proteins (~19%) showed more than a 2-fold change in abundance in either nuclear or cytosolic fractions ( Figures 1A-1C -1D, Table S1 ). Among the most differentially abundant proteins in nucleus and cytosol fractions, we observed the upregulation of Lef1 in FLA2 leukemic stem cells, a transcription factor and critical effector of the canonical Wnt/β-catenin signaling pathway involved in HSC selfrenewal. 15 
Ectopic expression of Lef1 in bone marrow cells leads to development of acute
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From myeloid leukemia when transplanted in mice. 16 The increased expression of the tumor suppressor Ing5 in the nucleus of FLB1 cells is also interesting. This protein is part of the chromatin remodeling MOZ/MORF and HBO1 complexes and stimulates their acetyltransferase activity. 17 ING5 also interacts with p53 and enhances its transcriptional activity associated with growth arrest and apoptosis. 18 High nuclear expression of ING5 was found to correlate with differentiation status of head and neck squamous cell carcinomas. 19 Most of the differentially expressed proteins identified have no known function in stem cell self-renewal or cancer. Of the 205 proteins most highly differentially expressed in FLA2, only 5 have previously been associated with hematopoietic stem cell activity, namely Dnmt1, Nup98, Fgfr1, Lef1, and CD34 (Table   S1 ). 16, [20] [21] [22] [23] To determine if differences in protein expression were also observed at the mRNA transcript level, we compared the proteomic data with previous RNA-seq data of FLA2 and FLB1 leukemias 8 ( Figure S2 ). An up-regulation of gene and protein expression levels was observed for Car2, Gsn (gelsolin), S100a9, BC117090, Stfa1 and 2010005H15Rik (bottom left quadrant of Figure S2 ). Gsn is required for the assembly and disassembly of actin filaments, and negatively regulate p53 mediated apoptosis by preventing its nuclear translocation. 24 S100a9 is a Ca 2+ binding protein and a regulator of pro-inflammatory responses and pre-metastatic niche formation. 25 Interestingly, BC117090, Stfa1 and 2010005H15Rik are contiguous genes on chromosome 16, but their functions are either unknown or not fully characterized. However, we noted a lack of correlation in expression levels for a large proportion of genes and proteins from our datasets, suggesting intensive post-transcriptional and post-translational regulation.
We next examined the differences in the status of protein phosphorylation between nuclear and cytosolic extracts derived from FLA2 and FLB1 leukemias ( Figure S1B ). This analysis led to the identification of 11,543 unique phosphopeptides from 1,987 phosphoproteins (9,459 phosphorylation sites, FDR <1%). Label-free quantitative proteomics enabled the correlation of abundance for 9,220 phosphopeptides (1, indicated that 7,480 sites (~80 %) have not been previously reported. We also evaluated the confidence level in the site localization using a probability score function 12, 26 and determined that 70% of the identified sites (6,622 sites) corresponded to high confidence assignments ( Figure 1E ). Analysis of the distribution of phosphorylation sites by amino acids indicates that phosphotyrosines account for 3.6 % of all identified phosphorylation sites ( Figure 1F ). Among the most differentially abundant phosphoproteins in nucleus and cytosol, increased phosphorylation of Son at serines 1987/1989/1991 in the cytosolic fraction of FLA2 cells is interesting since this protein interacts with ETO and inhibits the leukemogenic activity of the AML1-ETO fusion protein often found in AMLs. 27 However, abnormal cytoplasmic localization of SON has been found in AML1-ETO positive cell lines and in patient samples, and appears to collaborate with AML1-ETO to For personal use only. on October 22, 2017. by guest www.bloodjournal.org From generate leukemia. Phosphorylation of the high mobility group protein Hmga1 at S102 and S103 is increased 14-fold in FLA2 cells. HMGA1 is overexpressed in human leukemias and many other types of tumors. 28 Other members of this family have been shown to expand hematopoietic stem cells when overexpressed (Hmgb1) and promote neural stem cell self-renewal (Hmga2). 29, 30 Interestingly, many of the differentially phosphorylated proteins that have been previously associated with HSC activity are chromatin modifying proteins, like Myst3, Dnmt3a/b and Ezh2 (Table S2 ). [31] [32] [33] These results suggest that post-translational mechanisms affect the protein content of FLA2 and FLB1 leukemias and that phosphorylation-mediated signaling in the leukemic stem cell enriched leukemia (FLA2) differs from a leukemia with a lower content of self-renewing leukemic blasts (FLB1).
Protein interaction network analysis in leukemia stem cells
To get more functional insights into the proteins and pathways differentially regulated in LSCs, we conducted a bioinformatic analysis of our proteomics and phosphoproteomics data. First, we used the protein expression and phosphorylation data to develop an interaction network using the STRING program (http://string.embl.de). We combined interactions found in mouse and their human orthologs, resulting in a network of 2,779 proteins (nodes) and 29,386 connections (edges). From this complex network we extracted sub-networks using Gene Ontology (GO). Groups of proteins with specific GOterms changing in abundance or phosphorylation status were compared to all identified proteins. GO-terms were considered significant when they had adjusted p-values <0.05 in a Fisher exact test, resulting in 165 significant terms. Protein groups were then sorted according to Cellular Component, Biological Processes and Molecular Function GO categories ( Figure 2 , Table S3 ). From this analysis, statistically significant enrichment of four major groups of differentially regulated protein networks between FLA2 and FLB1 were identified ( Figure 3 ). These groups include: 1) Chromatin and histone modifiers (p=0.0005), 2) proteins involved in nuclear import/export (p=0.01) 3) Protein kinases (p=0.011) and 4) proteins involved in RNA processing (p=0.015).
Many chromatin and histone modifiers are known to affect stem cells or are implicated in cancer (reviewed in 34, 35 ). More than 50 different chromatin modifying proteins were found differentially regulated between FLA2 and FLB1 cells, mostly by phosphorylation (11 differentially expressed proteins versus 46 differentially phosphorylated) ( Figure 3 , Tables S1-S2). In addition to Polycomb Group proteins, members of the ISWI and Mi-2 complexes as well as DNA methyltransferases and methylated DNA binding proteins were differentially regulated. Histone deacetylases (Hdac1/2, Sirt2/7) and chromodomain proteins of the CHD and HP1 families also displayed multiple differentially phosphorylated residues. Interestingly, the only two proteins found to be more abundant in FLA2 leukemic stem cells, Dnmt1 and Brd4, are involved in the transmission of transcriptional programs to daughter cells. The former is thought to maintain DNA methylation patterns after DNA replication, while the latter is involved in gene bookmarking, an epigenetic mechanism allowing daughter cells to reproduce an inherited pattern of gene expression after mitosis. 36, 37 Strikingly, more than 27% of the 199 identified proteins involved in RNA processing were differentially expressed (n=13) or regulated by phosphorylation (n=44), suggesting that post-transcriptional regulation of mRNAs and ncRNAs by degradation, splicing or differential transport differs significantly between FLA2 and FLB1 leukemic cells ( Figure 3 and Tables S1-S2). In support of this, analysis by RNA-seq revealed numerous structural differences between the FLA2 and FLB1 transcriptomes, namely alternative splicing and promoter usage. 8 Nuclear Pore proteins and factors involved in nuclear import/export were also significantly enriched in our proteomics analysis. Of the 20 most differentially regulated proteins from this group, 11 varied in expression whereas 10 were phosphorylated in either FLA2 or FLB1. Differential regulation of proteins forming the nuclear pore was considerably more prevalent in FLA2 cells than FLB1, with 9 nucleoporins either more expressed (n=5) or phosphorylated (n=4) (Figure 3 , Tables S1-S2). Notably, expression of the nucleoporin Nup98 was increased ~3-fold in FLA2 leukemic stem cells. This protein is often implicated in recurrent chromosomal translocation in acute myeloid leukemias. 38 Contrary to nuclear pore constituents, import/export proteins like Ntf2, Importins and Rae1l were more expressed or phosphorylated in FLB1 cells (Figure 3 , Tables S1-S2 ). Together, these results suggest that the nuclear transport machinery of proteins and RNA behaves differently within the two leukemias.
Several serine/threonine kinases displayed differential regulation between FLA2 and FLB1 cells. Of the 81 protein kinases identified, 12 showed differences in protein abundance while 32 were differentially phosphorylated ( Figure 3 and Tables S1-S2). The CMGC and STE families represented almost half of the differentially regulated kinases ( Figure 3 ). Most of the phosphosites detected in our study fall outside of the kinase activation loops, suggesting alternate regulatory roles in modulating kinase function (target specificity, protein interaction, subcellular localization, etc.). One of the few For personal use only. on October 22, 2017. by guest www.bloodjournal.org From kinases for which activity could be correlated by independent western blot experiments was p38 MAP kinase (Mapk14). Strikingly, we found that p38 MAP kinase was considerably more activated in FLB1 than FLA2 cells ( Figure 4A , Table S2 ). RNA transcript and total p38 MAPK protein levels were similar in both leukemias ( Figure   4B ) 8 . Interestingly, we observed that the levels of p38 activation were inversely correlated with the self-renewal capacity of LSC ( Figure S4 ). Furthermore, replicate experiments performed on mice injected with FLB1 cells and treated with the p38 inhibitor SB203580 during the last week of leukemia development failed to show a reduction in LSC frequency ( Figure S5) . These results suggest that other effectors beside p38 are implicated in LSC self-renewal.
Increased activation of p38 and its downstream targets Msk1 and Mapkapk2 in the lower self-renewing FLB1 cells was confirmed by western blot analysis ( Figure 4B ). Importantly, high activated p38 MAPK levels have been shown to impair stem cell selfrenewal and induce differentiation of immature cells [39] [40] [41] . Activation status of other kinases known to have a role in stem cells and cancer, like Erk1/2, Jnk, Akt1, mTOR and Jak-STAT pathways, was further assessed. Despite being activated, no major differences between FLA2 and FLB1 cells were observed ( Figures 4C-4D ). Together, this suggests that activation of p38 MAPK and its downstream targets is a major signaling pathway that inversely correlates with the self-renewal potential of leukemic stem cells.
Polycomb Group protein phosphorylation and localization in FLA2 versus FLB1
Analysis of the FLA2 and FLB1 phosphoproteome datasets revealed multiple phosphorylation sites in chromatin modifying PcG proteins (Table 1) . Phosphopeptides for 2 proteins of the PRC2 complex (Ezh2, Suz12) and 6 of the PRC1 complex (Cbx8, Bmi1, Phc3, L3mbtl2, L3mbtl3 and Sfmbt1) were identified by mass spectrometry (Figure 3 , Table 1 ). For some of these proteins, only a few peptides were identified and protein expression data could not be obtained for all of them (Table S1) . At the mRNA level, quantitative RT-PCR analysis of all 37 known PcG genes revealed no significant expression differences between FLA2 and FLB1 cells ( Figures S3A-S3B ). Interestingly, phosphorylation of L3mbtl3 on serine 605 was found to be 3.5-fold higher in FLA2 cells (Table 1) . Conversely, phosphorylation of the Ezh2 threonine 487 (T487) and Suz12 serines 548 and 585 is more abundant in FLB1 than FLA2 leukemic cells ( Figures S3C-S3D ). This suggests that the function of both PRC1 and PRC2 complexes is differentially regulated by phosphorylation in leukemic stem cells.
The Jarid2 histone demethylase, which associates with the PRC2 complex and modulates its methyltransferase activity, 42, 43 was also 5.7-fold more phosphorylated in FLB1 than FLA2 (Table S2 ).
The PRC2 polycomb complex catalyzes the trimethylation of lysine 27 of histone H3 (H3K27me3), a crucial silencing epigenetic mark with roles in cell fate determination and cancer progression (reviewed in 44 ). Two recent studies showed that Ezh2, the enzyme responsible for H3K27me3, can be phosphorylated at T487 by CDK1. 45, 46 Whether this post-translational modification inhibits Ezh2 methyltransferase activity remains unclear as both studies reported conflicting results. We therefore tested whether the increased phosphorylation of Ezh2 T487 observed in FLB1 cells correlated with changes in global H3K27me3 levels. Western blots analysis of H3K27me3 failed to reveal any difference between FLA2 and FLB1 leukemias ( Figure S3E ). Global levels of other histone modifications like H3K4me3 and H3K9ac were also similar between both leukemias ( Figure S3E) . Interestingly, the phosphopeptide IGEGpTpYGVVYK, common to the first three Cdk isoforms, is 5.1-fold more abundant in FLB1 cells despite having similar cell cycle profile as FLA2 cells (Table S2 and data not shown). The inhibitory phosphorylation status of one or all of these Cdk isoforms thus appears to be inversely correlated with the higher phosphorylation of Ezh2 T487 in FLB1 leukemic cells, suggesting that either another kinase targets this residue or that phosphorylation status vary significantly among these Cdks.
The Ezh2 T487 residue is located close to the second SANT domain. It is highly conserved from Drosophila to Humans, but is replaced by an asparagine in the Ezh1 paralog ( Figure 5C ). This T487 residue is located only three amino acids upstream of a putative nuclear localization site (NLS), suggesting that phosphorylation of Ezh2 T487 may affect its localization. Strikingly, immunofluorescence staining of freshly isolated FLA2 and FLB1 cells reveals that Ezh2 is predominantly localized in the nucleus of FLA2 leukemic stem cells whereas it is predominantly cytoplasmic in FLB1 cells ( Figure   5D ). Accordingly, mass spectrometry results revealed a ~2-fold decrease in protein levels of both Ezh2 and its partner Suz12 in the nucleus of FLB1 cells compared to FLA2 (data not shown). These results were confirmed by western blot analyses ( Figures 5E-5F ).
Whether phosphorylation of Ezh2 T487 is directly involved in this differential localization remains to be tested. protein. 47 Until now, their subcellular localization had never been assessed. Surprisingly, we found specific cytoplasmic localization of Eed isoform 1 in both FLA2 and FLB1 while isoform 2 is solely nuclear, suggesting subcellular localization-specific differences in the composition of the core PRC2 complex ( Figure 5E ). Interestingly, Eed isoform 2 has only been identified in undifferentiated ES cells and in tumors. 48 Together these results indicate that differences in post-translational modifications and subcellular localization of PRC2 proteins distinguish highly self-renewing leukemic cells (FLA2) from non-reconstituting leukemic cells (FLB1) without affecting global levels of H3K27me3.
DISCUSSION
We report here the first large-scale quantitative proteome and phosphoproteome analyses of mouse acute myeloid leukemias, which include the most comprehensive datasets from a highly enriched primary stem cell population (FLA2: frequency of 1 in 1.4 LSC).
Several other groups have analyzed the proteome and the phosphoproteome of selfrenewing embryonic stem (ES) cells revealing quantitative changes of the protein content upon differentiation. [49] [50] [51] In this study, when comparing leukemic stem cells to leukemic blasts with lower self-renewal potential, major differences in protein abundance and phosphorylation were found, indicating distinct regulation of signaling pathways in leukemic stem cells (FLA2). Importantly, proteins implicated in chromatin and histone modification, RNA processing, nuclear import/export and protein kinases constitute the most differentially regulated networks. Among these, activation levels of the p38 MAPK pathway and differential phosphorylation and subcellular localization of Polycomb PRC2 proteins distinguish leukemic stem cells from lower self-renewing leukemic cells.
The Polycomb Group proteins are critical epigenetic regulators of cell fate and cancer development. 44 By inducing a repressive chromatin state and other non-histone functions, PcG proteins regulate multiple cellular programs essential for stem cell activity, such as cell cycle checkpoints, DNA damage repair, differentiation, apoptosis and senescence. Differential regulation of Polycombs between FLA2 and FLB1 leukemias is therefore likely to have an impact on their self-renewal potential. The effect of phosphorylation on PcG protein activity is still poorly understood. However, studies found that phosphorylation of BMI1 by the MK3 kinase induces its dissociation from chromatin, while AKT-mediated phosphorylation of Ezh2 at serine 21 suppresses its For personal use only. on October 22, 2017. by guest www.bloodjournal.org From H3K27 methyltransferase activity and derepresses silenced genes. 52, 53 Consistent with a role in cell fate, recent evidence now indicates that p38 MAPK-mediated phosphorylation of Ezh2 threonine 367 (T367) promotes formation of a repressive PRC2 complex that prevents expression of Pax7 required for muscle stem cell activity. 40 Together, this suggests that cell signaling pathways can post-translationally modify PRC2 activity to alter cell fate.
In this study, we found increased phosphorylation of L3mbtl3 S605 in FLA2 leukemic stem cells, whereas Ezh2 T487 and Suz12 S548 and S585 were more phosphorylated in the lower self-renewing FLB1 cells. The effect of these posttranslational modifications on leukemic stem cells activity is still obscure and will have to be further characterized. The Ezh2 T487 is embedded in a putative proline-directed kinase site. Recently, activation of the proline-directed CDK1 kinase was found to phosphorylate Ezh2 T487 thereby promoting derepression of osteogenic genes in mesenchymal stem cell. 46 This argues for a role of Ezh2 T487 phosphorylation in stem cell differentiation. However, we observed that increased phosphorylation of Ezh2 T487 in FLB1 cells correlated with an increase in the inhibited form of one or all of the first three Cdk isoforms. Thus, it remains possible that Ezh2 T487 may be phosphorylated by another proline-directed kinase in FLB1 leukemic blasts.
Interestingly, an inverse correlation between the activation state of the p38 MAPK kinase pathway and the self-renewal activity of FLA2 leukemic stem cells was observed.
The proline-directed p38 MAPK kinase plays a major role in the self-renewal potential of stem cells. [39] [40] [41] High p38 MAPK activation levels restrict cell proliferation, induce differentiation and limit the lifespan of hematopoietic stem cells. 39 Accordingly, For personal use only. on October 22, 2017. by guest www.bloodjournal.org From pharmacological inhibition of p38 MAPK restores the long-term repopulating potential of HSC in vivo. The p38 MAPK kinase downstream targets mediating these critical effects are much less characterized. However, the recent finding that p38 MAPK-mediated Ezh2 T367 phosphorylation induces muscle stem cells to differentiate 40 indicates that posttranslational regulation of PcG proteins is a key step. In this study, Ezh2 T367 phosphorylation levels did not change between FLA2 and FLB1 cells (Table 1 ).
However, it remains possible that p38 MAPK also target Ezh2 at T487. It will be interesting to test if p38 MAPK can indeed phosphorylate this residue and affect Ezh2's function.
The differential cellular distribution of Ezh2 and Suz12, located in the nucleus of leukemic stem cells (FLA2) and mostly in the cytoplasm of lower self-renewing leukemic cells (FLB1) is striking. In addition, we found for the first time differential localization of Eed isoforms 1 and 2 in leukemic cells. PRC2 proteins have been found previously in the cytoplasm. Activation of the TCR or PDGF receptors induces the translocation of Ezh2 in the cytoplasm where it regulates actin polymerization. 54 Similarly, activation of the TNF receptor 1 (TNFR1) induces translocation of EED in the cytoplasm where it interacts with a TNFR1-FAN-RACK1-complex to activate neutral sphingomyelinase 2, an enzyme that generates stress-induced ceramide. 55 Interestingly, blocking of TNFR1 signaling using anti-TNF-α antibodies inhibits p38 MAPK-mediated phosphorylation of Ezh2 at T367 leading to an accumulation of muscle stem cells. 40 This suggests a potential link between TNFR1 signaling, p38 activation, Ezh2 phosphorylation and cytoplasmic localization of PRC2 proteins. Other receptors involved in stem cells and cancer development, like integrins have also been shown to induce cytoplasmic translocation of PRC2 proteins For personal use only. on October 22, 2017. by guest www.bloodjournal.org From when activated, 56, 57 further supporting a non-chromatin cytoplasmic function for PRC2 proteins. The mechanism of PRC2 protein nuclear/cytoplasmic shuttling is still unknown.
However, it is possible that phosphorylation of the Ezh2 T487 residue, next to a putative nuclear localization site, regulates this process. Further studies will have to be conducted to test this.
Global levels of the PRC2-mediated H3K27me3 chromatin mark were similar between FLA2 and FLB1 cells, despite Ezh2 being more present in the cytoplasm of FLB1 cells. Changes in H3K27me3 may affect only a small proportion of the histone population undetectable by immunoblots. Alternatively, the remaining levels of Ezh2 in the nucleus of FLB1 cells may be sufficient to maintain global levels of H3K27me3. The Ezh1 paralog may also compensate for lower Ezh2 levels in the nucleus. In any case, this does not mean that there are no differences between the chromatin landscapes of FLA2 and FLB1 leukemic cells. Local differences in PcG-repressed target genes between FLA2 and FLB1 cells have not been tested, but likely differ abundantly, as suggested by the differences in their transcriptome profile. 8 In addition to p38 MAPK signaling and PcG proteins, the fact that three of the most differentially regulated groups of proteins between FLA2 and FLB1 are involved in RNA processing, nuclear import/export and chromatin remodeling is particularly interesting. By establishing epigenetic chromatin states and participating in multiple essential processes such as DNA replication, DNA damage repair, chromosome condensation/segregation and transmission of transcriptional programs through cell divisions, chromatin modifiers are increasingly recognized as key factors of cell fate. 35 They are also widely implicated in cancer development. Regulation of chromatin modifiers function by phosphorylation has not been extensively studied, but given the importance of establishing specific epigenetic states for stem cell activity, posttranslational modulation of these proteins offers a link between signaling pathways and chromatin to regulate self-renewal and tumorigenesis.
The potential impact of distinct regulation of RNA processing proteins on the transcriptional program of leukemic stem cells is supported by a previous RNAsequencing study on FLA2 and FLB1 cells showing considerable structural differences in their transcriptome, such as alternative splicing and promoter usage. 8 The importance of RNA processing is further substantiated by studies reporting increased alternative splicing in stem cells for many signaling pathway components known to govern selfrenewal and differentiation. 58 This assuredly induces important changes in the selfrenewal properties of stem cells (whether normal of cancerous). Furthermore, modifications in the Nuclear Pore Complex (NPC) and other proteins involved in nucleocytoplasmic transport is expected to affect many cellular processes by regulating the proper localization of RNAs and signaling proteins. The nuclear pore protein NUP98 is well known for its leukemic potential when fused to a variety of genes. 38 Moreover, fusion of NUP98 to the homeodomain of HOXA10 can massively expand HSCs ex vivo when expressed in these cells, suggesting an important role for this protein in regulating self-renewal pathways. 20 A recent report also indicates that NPC composition is important for differentiation of stem cells and embryo development, as Nup133-deficient ES cells fail to differentiate correctly, although the NPC assembles correctly. 59 In addition, these processes are intimately connected to each other. Recent studies found that splicing factors interact with chromatin remodeling enzymes. Specific
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From chromatin structures and histone modifications also appear to dictate alternative splicing patterns (reviewed in 60 ). Multiple interactions also occur between RNA processing proteins and the nuclear pore import/export machinery, allowing coordination between transcription and mRNA transport. 61 Moreover, nucleoporins have been found to interact directly with chromatin and chromatin modifiers to regulate the transcriptional output of target genes. 62, 63 Nucleoporins are thought to help define heterochromatin-euchromatin boundaries and a large part of the nuclear architecture and higher order chromatin structure occurs through nuclear pore complexes serving as docking sites for chromatin.
The nuclear lamina which makes contacts with nuclear pores, chromatin and chromatin modifiers is also involved in chromatin looping and spatial organization of the genome. 64 Accumulating data suggests that spatial organization of chromatin through the nuclear lamina may be important in establishing transcriptional programs and maintaining specific cell states. 65 Interestingly, many nuclear lamina-associated proteins, like Lmnb1/2, Lbr, Nsun2, Tmpo and Safb were differentially regulated between FLA2 and FLB1 (Tables S1-S2). Together, this suggests that differential regulation of RNA processing, nuclear import/export, chromatin modifiers and the nuclear lamina may collaborate together in establishing a permissive or restrictive self-renewal program.
This study constitutes a unique resource for cancer and stem cell biologist to start dissecting candidate proteins and pathways implicated in self-renewal of leukemic stem cells. The vast number of differentially regulated proteins identified suggests that multiple pathways are at play, mainly chromatin modifiers, RNA processing and nuclear import/export. Future work will show if and how they are connected to allow leukemic stem cells to self-renew. 
